Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and synthesis editing and related services. The B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. The Company provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.

Employees

3,000

Sector

Biotechnology & Medical Research

Calendar

05-10 - Q2 2026 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
13/02/26	28.62 $	+1.78%	800,282
12/02/26	28.12 $	-7.65%	841,846
11/02/26	30.45 $	+1.53%	1,007,331
10/02/26	29.99 $	+0.64%	1,011,918
09/02/26	29.80 $	+3.76%	1,136,871

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

28.62USD

Average target price

38.67USD

Spread / Average Target

+35.10%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
28.62 ^USD	+1.78%		-0.35%	-13.95%

02-09	Azenta Teams Up With Frontier Space for Space-Based Scientific Experiments	MT
02-09	Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure	CI

Capitalization	1.32B 1.11B 1.01B 967M 1.8B 119B 1.87B 11.78B 4.68B 57.66B 4.94B 4.84B 202B	P/E ratio 2026 *	-196x	P/E ratio 2027 *	63.3x
Enterprise value	1.32B 1.11B 1.01B 967M 1.8B 119B 1.87B 11.78B 4.68B 57.66B 4.94B 4.84B 202B	EV / Sales 2026 *	2.13x	EV / Sales 2027 *	2.02x
Free-Float	74.95%	Yield 2026 *	-	Yield 2027 *	-

02-09	Azenta Teams Up With Frontier Space for Space-Based Scientific Experiments	MT
02-09	Azenta Life Sciences and Frontier Space Announce Strategic Partnership to Advance Space-Based Life Sciences Research Infrastructure	CI
02-04	Azenta, Inc., Q1 2026 Earnings Call, Feb 04, 2026
02-04	Azenta Shares Drop After Fiscal Q1 Results	MT
02-04	Azenta, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-04	Azenta, Inc. Reiterates Earnings Guidance for Full Year Fiscal 2026	CI
02-04	Tranche Update on Azenta, Inc.'s Equity Buyback Plan announced on December 10, 2025.	CI
02-04	Azenta Fiscal Q1 Non-GAAP Earnings Fall, Revenue Rises; Shares Down Pre-Bell	MT
02-04	Earnings Flash (AZTA) Azenta, Inc. Reports Q1 Revenue $149.0M, vs. FactSet Est of $147.1M	MT
02-04	Earnings Flash (AZTA) Azenta, Inc. Posts Q1 Adjusted EPS $0.09 per Share, vs. FactSet Est of $0.14	MT
02-02	Azenta, Inc. Announces Resignation of Alan P. Malus from Board of Directors and Member of Human Resources and Compensation Committee, Effective January 29, 2026	CI
01-29	Gartner, Inc. Announces Board Appointments, Effective from January 29, 2026	CI
12-29	Azenta to Sell B Medical Systems Business	MT

12-19	Needham Raises Price Target on Azenta to $44 From $42, Keeps Buy Rating	MT
11-24	Needham Raises Price Target on Azenta to $42 From $40, Keeps Buy Rating	MT
30/10/25	Jefferies Upgrades Azenta to Buy From Hold, Adjusts Price Target to $38 From $30	MT
06/08/25	Raymond James Upgrades Azenta to Outperform From Market Perform	MT
07/05/25	Needham Adjusts Price Target on Azenta to $40 From $59, Keeps Buy Rating	MT

Azenta, Inc. Share Price

Equities

AZTA

US1143401024

Biotechnology & Medical Research

Valuation: Azenta, Inc.

Chart: Azenta, Inc.

Latest news: Azenta, Inc.

Last Transcript: Azenta, Inc.

Analysts' recommendations: Azenta, Inc.

Press Releases: Azenta, Inc.

News in other languages: Azenta, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Azenta, Inc.

ETFs: Azenta, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

14/07/22	MÄRKTE USA/Börse erholt von Tagestief - Zinsängste lassen nach
14/07/22	MÄRKTE USA/Wall Street erholt von Tagestief
14/07/22	MÄRKTE USA/Wall Street weiter auf Talfahrt
14/07/22	MÄRKTE USA/An Wall Street dürfte es weiter abwärts gehen
15/06/21	NIKE : les concurrents du géant cèdent devant ses performances

1 day	+1.78%
1 week	-0.35%
Current month	-26.39%
1 month	-27.54%
3 months	-3.80%
6 months	-6.44%
Current year	-13.95%

1 week	27.71	30.74
1 month	27	41.73
Current year	27	41.73
1 year	23.91	47.55
3 years	23.91	69.16
5 years	23.91	124.79
10 years	8.6	124.79

Manager	Title	Age	Since
John Marotta CEO	Chief Executive Officer	45	08/09/2024
Lawrence Lin DFI	Director of Finance/CFO	49	30/11/2024
Rob Woodward CTO	Chief Tech/Sci/R&D Officer	-	31/10/2009

Director	Title	Age	Since
Robyn Davis BRD	Director/Board Member	65	27/06/2013
Erica McLaughlin BRD	Director/Board Member	50	02/04/2020
Frank Casal CHM	Chairman	72	29/01/2024

Name		Varia. Jan 1.	Weight	AuM
GLOBAL X ROBO GLOBAL ROBOTICS & AUTOMATION ETF - AUD		+3.71%	1.74%	147 M€
FIRST TRUST ALPHADEX U.S. TECHNOLOGY SECTOR INDEX ETF - CAD		-2.71%	0.21%	17 M€

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AZENTA, INC.	+1.78%	-0.35%	-36.97%	-37.07%	1.32B
LONZA GROUP AG	+4.62%	+0.73%	-12.88%	-4.40%	47.61B
BEONE MEDICINES AG	-0.10%	-2.22%	+49.90%	+43.32%	38.3B
CELLTRION, INC.	-0.21%	+8.18%	+39.13%	+61.33%	36.11B
IQVIA HOLDINGS INC.	-1.13%	-10.96%	-13.70%	-26.48%	28.31B
REVOLUTION MEDICINES, INC.	-1.05%	-1.21%	+136.81%	+277.83%	18.62B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+7.58%	+14.65%	+31,531.21%	+4,137.24%	15.44B
EUROFINS SCIENTIFIC SE	+2.25%	-3.74%	+29.62%	-3.02%	13.71B
ASCENDIS PHARMA A/S	-0.82%	-2.62%	+50.14%	+94.88%	13.28B
IONIS PHARMACEUTICALS, INC.	-1.44%	-6.82%	+159.66%	+105.56%	13.06B
Average	+1.15%	-0.91%	+3,193.29%	+464.92%	22.57B
Weighted average by Cap.	+1.23%	-0.92%	+2,191.66%	+330.04%

	2026 *	2027 *
Net sales	618M 521M 475M 454M 842M 55.99B 875M 5.53B 2.19B 27.04B 2.32B 2.27B 94.5B	653M 550M 502M 479M 889M 59.15B 924M 5.84B 2.32B 28.56B 2.45B 2.4B 99.83B
Net income	6.75M 5.69M 5.19M 4.95M 9.2M 612M 9.56M 60.36M 23.96M 295M 25.32M 24.8M 1.03B	28.59M 24.09M 21.97M 20.98M 38.94M 2.59B 40.46M 256M 101M 1.25B 107M 105M 4.37B
Net Debt	-	-